Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arthritis Drug Of Japan’s Chugai, Roche Shows Well In Phase III Trial

This article was originally published in PharmAsia News

Executive Summary

A drug developed by Japan's Chugai Pharmaceutical and Switzerland's Roche Holdings is showing favorable results midway through a Phase III study for reducing joint damage from rheumatoid arthritis. The drug is Actemra (tocilizumab), the subject of a delay by the U.S. FDA in reviewing it for possible approval. FDA wanted more data related to manufacturing and labeling, according to Roche. Researchers said the ongoing study shows Actemra to be effective in slowing the progression of bone erosion when used over a four-week period with methotrexate. The drug is expected to be a billion-dollar seller for the two drug makers once approved. (Click here for more
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066985

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel